BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05450692 (Ceralasertib in 2L+ NSCLC without actionable genomic alterations): BVCT ex-ante prediction vs. reported outcome

On 11 Apr 2025, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 22 Dec 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05450692
Acronym
LATIFY
Drug Name
Ceralasertib
Drug MoA
ATR inhibitor
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
2L+ NSCLC without actionable genomic alterations (AGAs)
Human Patients
594
Sponsor
AstraZeneca
Phase
Phase 3

Prediction of , index 1964

Prospective Prediction
Prediction Index
1964
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit in OS inferior to docetaxel)
Technical Prediction
FAILURE (statistically insignificant clinical benefit in ORR/PFS inferior to docetaxel)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
255 days in advance
Readout Data Interpretation
Ceralasertib + durvalumab did not meet primary endpoint of OS vs docetaxel; safety profile consistent with individual agents.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
Phase
Phase 3
Status
Active not recruiting
Enrollment
594
Lead sponsor
AstraZeneca
Conditions
Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
DRUG: Ceralasertib; DRUG: Durvalumab; DRUG: Docetaxel
Design
Randomized · Parallel · None
Primary purpose
Treatment
Start
2022-09-15
Primary completion
2025-10-06
Completion
2027-12-31
Primary outcomes
  • Overall Survival (OS) (Every 3 months (± 1 week) following objective progression of disease (PD) or treatment discontinuation (up to three years))

NCT05450692 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials